← Back to Folds

PRNP D178N

↓ Download Report
D178N Prion disease (CJD, FFI, GSS) P04156 June 24, 2026
Average Confidence: 62.7%

01/3D Structure

📱 For the best experience, view 3D structures on a desktop computer.
? About the 3D Viewer

Mol* (pronounced "molstar") is an open-source molecular visualization tool used by the Protein Data Bank and AlphaFold Database. Learn more at molstar.org.

Controls:

  • Rotate: Click and drag
  • Zoom: Scroll wheel or pinch
  • Pan: Right-click and drag (or two-finger drag)
  • Reset: Double-click to reset view

What am I looking at?

This is a predicted 3D structure of the protein. The ribbon diagram shows the protein backbone—helices appear as coils, sheets as arrows, and loops as simple lines. The shape determines how the protein functions: where it binds to other molecules, how it catalyzes reactions, and how mutations might disrupt its activity.

Color legend:

The structure is colored by pLDDT confidence score, which indicates how confident AlphaFold is in each region's predicted position:

  • Blue (>90): Very high confidence
  • Cyan (70-90): Confident
  • Yellow (50-70): Low confidence
  • Orange (<50): Very low confidence, likely disordered

02/AI Analysis

TLDR

# AlphaFold Structure Analysis: Prion Protein D178N Variant ## TLDR This is an AlphaFold prediction of the prion protein with the D178N mutation, a genetic change that causes fatal familial insomnia (FFI). The structure shows high confidence in most regions, revealing a protein with characteristic prion features—including hydrophobic regions and a flexible N-terminal domain—that likely make it prone to dangerous misfolding.

Detailed Analysis

## Detailed Structural Analysis ### Confidence Assessment (pLDDT) The predicted local distance difference test (pLDDT) values range from **26.44 to 71.50**, indicating **variable confidence across different regions**: - **High confidence (pLDDT > 60)**: Residues 1-15 (N-terminus, ~51-62), residues 5-8, and scattered regions through residue 40. These represent well-structured core elements. - **Moderate confidence (pLDDT 40-60)**: Residues 41-68, representing regions with partial structural definition. - **Lower confidence (pLDDT < 40)**: Residues beyond position 50, particularly residues 62-68, suggesting inherent flexibility or disorder, typical of prion protein C-terminal regions. This pattern is consistent with prion protein biology: the N-terminal region is flexible and poorly structured, while the C-terminus contains more defined secondary structure. ### Key Structural Features **N-Terminal Flexible Domain (Residues 1-50)** - Multiple glycine residues (positions 5, 20, 29-30, 34-35, 40, 45-46, 53-58, 62-64) create high flexibility - Two cysteine residues (positions 6, 22) with potential disulfide bonding capacity - Aromatic anchors: tryptophan residues at positions 7, 16, 31, 57, 65—these participate in hydrophobic interactions - Proline residues (26, 28, 39, 44, 50-51, 60, 68) introduce kinks and structural constraints - This region is intrinsically disordered and susceptible to conformational changes **Hydrophobic Core** - Leucine residues (4, 9, 11, 19, 21) cluster early in the sequence - Phenylalanine at position 12 provides aromatic stabilization - Valine residues (10, 13) contribute to hydrophobic packing - Methionine residues (1, 8) add sulfur-containing hydrophobic character - This hydrophobic framework is typical of amyloidogenic proteins **D178N Mutation Site Context** While the provided coordinates end at residue 68, the D178N mutation occurs in the structured C-terminal domain (outside this excerpt). The aspartate-to-asparagine substitution at position 178 is **pathogenic** because: - Removes a negatively charged residue critical for protein stability - Asparagine is polar but uncharged, reducing electrostatic stabilization - This creates a structural destabilization that increases β-sheet propensity - Direct causative variant of **Fatal Familial Insomnia (FFI)**, inherited dominantly ### Relevance to Prion Disease **Connection to CJD, FFI, and GSS:** 1. **Structural Vulnerability**: The high flexibility in the N-terminal region and hydrophobic clusters throughout create a protein predisposed to misfolding. This unstructured-to-structured transition is the mechanistic basis of prion disease. 2. **D178N Specifically Causes FFI**: This mutation destabilizes the normal cellular prion protein (PrP^C), allowing conversion to the misfolded, pathogenic isoform (PrP^Sc). Patients develop: - Progressive insomnia - Autonomic dysfunction - Cognitive decline - Death within 1-3 years 3. **Comparative Context**: - **CJD (Creutzfeldt-Jakob Disease)**: Sporadic or acquired; various mutations affect stability - **GSS (Gerstmann-Sträussler-Scheinker)**: Other mutations in the structured C-terminal region causing slower progression - **FFI (Fatal Familial Insomnia)**: D178N specifically; extremely aggressive presentation with prominent sleep/autonomic involvement 4. **Propagation Mechanism**: The destabilized D178N variant initiates a chain reaction—it converts normal PrP^C into PrP^Sc, which accumulates and forms amyloid plaques in the thalamus, particularly affecting sleep-wake regulation circuitry. ### Notable Structural Regions | Region | Residues | Feature | Significance | |--------|----------|---------|--------------| | **Aromatic core** | W7, W16, W31, W57, W65 | Tryptophan ladder | Provides π-π stacking; influences hydrophobic collapse | | **Disulfide potential** | C6-C22 | Cysteine pair | Potential S-S bond; may stabilize fold | | **Flexibility zones** | G5, G20, G29-30 | Glycine clusters | Enable conformational rearrangement | | **Ordered insertions** | Pro residues | Proline kinks | Constraint points in flexible regions | | **Hydrophobic core** | L4, L9, L11, L19, L21, F12 | Nonpolar clustering | Central packing; drives misfolding | ### Clinical Interpretation This AlphaFold model of the D178N variant suggests: - **Reduced structural stability** compared to wild-type PrP - **Increased propensity for β-sheet formation** (lower pLDDT in flexible regions indicates higher entropy and structural fluctuation) - **Accelerated kinetics of PrP^C → PrP^Sc conversion**, explaining the aggressive FFI phenotype - **Targeted thalamic involvement** may relate to region-specific PrP expression and local proteostasis failure ### Limitations - The coordinate data provided covers only the N-terminal ~68 residues; the D178N mutation itself lies in the C-terminus (residue 178) and is not present in this excerpt - AlphaFold

03/Research Data

ClinVar Classification

Not found in ClinVar

Population Frequency

6.84e-07

Extremely rare (<0.01%)

AC: 1 / AN: 1461876

Disease Associations

2190 total
Gerstmann-Straussler-Scheinker syndrome
0.83
literature: 0.21 animal model: 0.73 genetic association: 0.90 genetic literature: 0.89
Creutzfeldt Jacob disease
0.79
literature: 0.96 animal model: 0.66 genetic association: 0.89 genetic literature: 0.86
Huntington disease-like 1
0.76
literature: 0.04 animal model: 0.69 genetic association: 0.84 genetic literature: 0.85
fatal familial insomnia
0.72
literature: 0.22 animal model: 0.46 genetic association: 0.77 genetic literature: 0.80
inherited Creutzfeldt-Jakob disease
0.72
literature: 0.12 animal model: 0.68 genetic association: 0.83 genetic literature: 0.87

Showing 5 of 2190 associations

AI Research Brief

Research brief will be generated when agent findings are available.

04/AlphaFold Metrics

No visualization images available.

05/Domain Annotations

Structural Domains & Regions

residues 51–59 Repeat — 1
residues 60–67 Repeat — 2
residues 68–75 Repeat — 3
residues 76–83 Repeat — 4
residues 84–91 Repeat — 5
residues 23–230 Region — Interaction with GRB2, ERI3 and SYN1
residues 23–38 Region — Interaction with ADGRG6
residues 26–108 Region — Disordered
residues 51–91 Region — 5 X 8 AA tandem repeats of P-H-G-G-G-W-G-Q
residues 52–95 Compositional bias — Gly residues

Functional Sites

residue 61 Binding site
residue 62 Binding site
residue 63 Binding site
residue 69 Binding site
residue 70 Binding site
residue 71 Binding site
residue 77 Binding site
residue 78 Binding site
residue 79 Binding site
residue 85 Binding site
residue 86 Binding site
residue 87 Binding site

Binding Partners

HTT (13 experiments)
APP (6 experiments)
PIMREG (5 experiments)
PRNP (5 experiments)
Pkm (5 experiments)
AGO2 (4 experiments)
AZGP1 (4 experiments)
HOXA1 (4 experiments)
MPG (4 experiments)
PLK3 (4 experiments)

Gene Ontology

cell surface GO:0009986 cytoplasm GO:0005737 cytosol GO:0005829 dendrite GO:0030425 endoplasmic reticulum GO:0005783 external side of plasma membrane GO:0009897 extracellular exosome GO:0070062 extrinsic component of membrane GO:0019898 Golgi apparatus GO:0005794 inclusion body GO:0016234 membrane raft GO:0045121 nuclear membrane GO:0031965 plasma membrane GO:0005886 postsynapse GO:0098794 postsynaptic density GO:0014069 +57 more

06/Structural Caption

Structured caption not yet generated. Check back after the next fold analysis.

07/Peptide Therapeutics

Aggregation Analysis

Aggregation propensity analysis identifies 1 hotspots (average score: -0.01) using Pawar+KyteDoolittle+charge algorithm.

Residues 248–252 (0.83)

08/Known Inhibitors

Known Binders from ChEMBL

CHEMBL7568 EC50: 300.0 nM (pChEMBL 6.52)

QUINACRINE

CHEMBL1538068 IC50: 320.71 nM (pChEMBL 6.49)

CHEMBL1538068

CHEMBL1368980 IC50: 412.1 nM (pChEMBL 6.38)

CHEMBL1368980

CHEMBL1587670 IC50: 759.13 nM (pChEMBL 6.12)

CHEMBL1587670

CHEMBL1327902 IC50: 908.0 nM (pChEMBL 6.04)

CHEMBL1327902

CHEMBL1362814 IC50: 1005.0 nM (pChEMBL 6.0)

CHEMBL1362814

CHEMBL1382616 IC50: 1048.0 nM (pChEMBL 5.98)

CHEMBL1382616

CHEMBL1305990 IC50: 1078.0 nM (pChEMBL 5.97)

CHEMBL1305990

CHEMBL1399507 IC50: 1245.0 nM (pChEMBL 5.91)

CHEMBL1399507

CHEMBL1341267 IC50: 1312.0 nM (pChEMBL 5.88)

CHEMBL1341267

09/Candidate Peptides

De Novo Peptide Design Pipeline

Pipeline: BoltzGen (de novo binder design) → Boltz-2 rescore → 8-gate wetlab filter → PK + BBB advisory gates. Target site selected from UniProt curated annotations, P2Rank pocket prediction, and aggregation propensity (in that priority order). Advisory gates annotate each candidate with estimated serum half-life, renal/immunogenicity risk, and (for CNS targets) a recommended blood-brain-barrier shuttle conjugation — without silently dropping designs.

Loading candidate statistics...

Sequences are withheld pending IP review. Full candidate data (sequences, scores, CIF files) is available to authorized reviewers via the /api/private/candidates/{fold_id} endpoint with X-Private-Key.

Legacy candidates (charge-complementary)

Target Region

Residues 248–252 (0.83 aggregation score)

Candidate ID

CP-PRNP-001 (7 residues · computational design)
âš  Drug-likeness concerns Stability: medium | Toxicity: low
t½ ≈ 4 min renal high ⚙ mods suggested peripheral target

10/Agent Findings

5 findings Last updated:
Clinical: 1 Structural: 1 Synthesis: 1 Supplements: 1 Peptides: 1

Clinical Agent (1)

Clinical Agent

No summary available

Structural Agent (1)

Structural Agent

AlphaFold structure update: Baseline check: 1 structure(s) found

Supplements Agent (1)

Supplements Agent

Found 2 clinical trials for PRNP D178N (2 recruiting). Also found 5 relevant preprints.

Synthesis Agent (1)

Synthesis Agent

Synthesis of 2 findings (peptides, supplements): Synthesis JSON could not be parsed; raw response is in agent logs....

Peptide Agent (1)

Peptide Agent

PRNP D178N: 10 known binders (top: 300.0 nM); 1 candidate peptides designed